Search

Your search keyword '"Dey, B.R."' showing total 15 results
Start Over Author "Dey, B.R."
15 results on '"Dey, B.R."'

6. Expression of α4β7 Integrin on Peripheral Blood Memory CD4+ T-Cells After Allogeneic HCT Correlates with Non-Relapse Mortality and Overall Survival

Author

Y.-B., Chen, primary, McDonough, S., additional, Chen, H., additional, Kennedy, J., additional, Alyea, E.P., additional, Armand, P., additional, Ballen, K.K., additional, Cutler, C., additional, Dey, B.R., additional, Ho, V.T., additional, Koreth, J., additional, McAfee, S.L., additional, Spitzer, T.R., additional, Antin, J.H., additional, Soiffer, R.J., additional, Jagasia, M., additional, and Ritz, J., additional

Published
2012
Full Text
View/download PDF

8. Ex Vivo Treatment of Hematopoietic Stem Cells With 16,16-Dimethyl Prostaglandin E2 (FT1050) Improves Engraftment and Hematopoietic Reconstitution

Author

Cutler, C.S., primary, Desponts, C., additional, Robbins, D., additional, North, T.E., additional, Goessling, W., additional, Kao, G., additional, Ritz, J., additional, Ballen, K.K., additional, Antin, J.H., additional, Spitzer, T.R., additional, SoifferChenY.-B.A., R.J., additional, Ho, V.T., additional, Armand, P., additional, Koreth, J., additional, Alyea, E., additional, McAfee, S., additional, Dey, B.R., additional, Shoemaker, D., additional, and Multani, P.S., additional

Published
2011
Full Text
View/download PDF

9. Increasing the Dose of Busulfan Results in Lower Relapse Rates and Higher Non-Relapse Mortality in Patients With MDS/AML Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

Author

Chen, Y.-B., primary, Sun, L., additional, Kim, H., additional, Alyea, E.P., additional, Armand, P., additional, Attar, E.C., additional, Ballen, K.K., additional, Cutler, C., additional, Dey, B.R., additional, Koreth, J., additional, McAfee, S.L., additional, Spitzer, T.R., additional, Antin, J.H., additional, Soiffer, R.J., additional, and Ho, V.T., additional

Published
2011
Full Text
View/download PDF

14. Myeloma Responses and Tolerance Following Combined Kidney and Nonmyeloablative Marrow Transplantation: In Vivoand In VitroAnalyses

Author

Fudaba, Y., Spitzer, T.R., Shaffer, J., Kawai, T., Fehr, T., Delmonico, F., Preffer, F., Tolkoff-Rubin, N., Dey, B.R., Saidman, S.L., Kraus, A., Bonnefoix, T., McAfee, S., Power, K., Kattleman, K., Colvin, R.B., Sachs, D.H., Cosimi, A.B., and Sykes, M.

Abstract

Six patients with renal failure due to multiple myeloma (MM) received simultaneous kidney and bone marrow transplantation (BMT) from HLA-identical sibling donors following nonmyeloablative conditioning, including cyclophosphamide (CP), peritransplant antithymocyte globulin and thymic irradiation. Cyclosporine (CyA) was given for approximately 2 months posttransplant, followed by donor leukocyte infusions. All six patients accepted their kidney grafts long-term. Three patients lost detectable chimerism but accepted their kidney grafts off immunosuppression for 1.3 to >7 years. One such patient had strong antidonor cytotoxic T lymphocyte (CTL) responses in association with marrow rejection. Two patients achieved full donor chimerism, but resumed immunosuppression to treat graft-versus-host disease. Only one patient experienced rejection following CyA withdrawal. He responded to immunosuppression, which was later successfully withdrawn. The rejection episode was associated with antidonor Th reactivity. Patients showed CTL unresponsiveness to cultured donor renal tubular epithelial cells. Initially recovering T cells were memory cells and were enriched for CD4+CD25+cells. Three patients are in sustained complete remissions of MM, despite loss of chimerism in two. Combined kidney/BMT with nonmyeloablative conditioning can achieve renal allograft tolerance and excellent myeloma responses, even in the presence of donor marrow rejection and antidonor alloresponses in vitro.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results